Drug intelligence / Profile preview

zirconium Zr-89-TAK-164

Development stage: Discontinued
Lead developer: Takeda
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

A radioimmunoconjugate composed of TAK-164 (an antibody-drug conjugate targeting guanylyl cyclase C) labeled with the radioisotope zirconium-89 (89Zr) via a DFO (desferrioxamine) chelator. It is designed for diagnostic imaging purposes to visualize GCC expression in gastrointestinal cancers, particularly colorectal cancer. The parent compound TAK-164 consists of a human IgG1 monoclonal antibody targeting GCC, linked to a DNA alkylating agent (mono-indolinobenzodiazepine pseudodimer or IGN) via a peptide linker.

Other names: zirconium Zr 89-TAK-164

Targets

GUCY2C (Guanylate cyclase C receptor)

Beyond the preview

Go deeper on zirconium Zr-89-TAK-164.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on zirconium Zr-89-TAK-164.

Explore the full profile